Crossmark

SMARCB1 is required for widespread BAF complex–mediated activation of enhancers and bivalent promoters

Crossref DOI link: https://doi.org/10.1038/ng.3958

Published Online: 2017-09-25

Published Print: 2017-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nakayama, Robert T

Pulice, John L https://orcid.org/0000-0002-2561-9358
Valencia, Alfredo M

McBride, Matthew J

McKenzie, Zachary M

Gillespie, Mark A

Ku, Wai Lim https://orcid.org/0000-0002-8859-6771
Teng, Mingxiang https://orcid.org/0000-0002-8536-8941
Cui, Kairong

Williams, Robert T

Cassel, Seth H

Qing, He

Widmer, Christian J

Demetri, George D

Irizarry, Rafael A

Zhao, Keji

Ranish, Jeffrey A https://orcid.org/0000-0001-7181-0287
Kadoch, Cigall https://orcid.org/0000-0002-4058-5985
License Information

Text and Data Mining valid from 2017-09-25
More Information

Article History

Received: 17 November 2016

Accepted: 29 August 2017

First Online: 25 September 2017

Competing interests

: C.K. is a scientific founder, shareholder and consultant of Foghorn Therapeutics, Inc. (Cambridge, Massachusetts).